The WHO recommended R21/Matrix-M vaccine may be the most effective solution to Malaria yet. But it is still not the perfect fix.
The vaccine meets WHO’s efficacy target of 75% against Malaria, which kills nearly 600,000 people every year. Most of them are children.
The Oxford-developed vaccine is the second one approved for global rollout. The other is reportedly limited, expensive and less effective.
The Serum Institute of India said it will produce 100 million doses of the vaccine and double production next year.
The new Malaria vaccine, which requires 4 doses, will reportedly cost $2 and $4 per jab. The cost is in line with other childhood vaccines in Africa.